Featuring slide presentations and related discussion from Drs Tanya B Dorff, Fred Saad, A Oliver Sartor and Matthew R Smith. (Video Program)
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUCancers21/Prostate/Presentations/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
Tanya B Dorff, MD
Associate Clinical Professor of Medicine
City of Hope National Medical Center
Department of Medical Oncology and Developmental Therapeutics
Head, Genitourinary Cancer Program
Los Angeles, California
Advisory Committee: AbbVie Inc, Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Janssen Biotech Inc; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Pfizer Inc.
Fred Saad, MD
Professor and Chief of Urology
Director of GU Oncology
Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
Director, Prostate Cancer Research
Montreal Cancer Institute/CRCHUM
Montréal, Québec, Canada
Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme.
A Oliver Sartor, MD
CE and Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana
Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien Muenchen AG, Janssen Biotech Inc, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals, TeneoBio, Theragnostics; Contracted Research: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Invitae, Janssen Biotech Inc, Merck, Progenics Pharmaceuticals Inc, Sanofi Genzyme, SOTIO LLC.
Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Advisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Exelixis Inc, Merck and Sanofi Genzyme.
Release date: April 2021
Expiration date: April 2022
After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.
(WIFI is recommended for best performance):